Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: possible relation to high bcl-2/bax ratio?
Autor: | Yechezkel Sidi, T. Livnat, Varda Rotter, G. Lilling, H. Hacohen, Jardena Nordenberg |
---|---|
Rok vydání: | 2000 |
Předmět: |
Cancer Research
medicine.medical_specialty Programmed cell death Neoplasms Hormone-Dependent Antineoplastic Agents Breast Neoplasms Biology chemistry.chemical_compound Bcl-2-associated X protein Estrogen Receptor Modulators Proto-Oncogene Proteins Internal medicine Gene expression Tumor Cells Cultured medicine Humans Neoplasm RNA Messenger skin and connective tissue diseases bcl-2-Associated X Protein Messenger RNA Estradiol Oligonucleotides Antisense medicine.disease Growth Inhibitors Tamoxifen Endocrinology Proto-Oncogene Proteins c-bcl-2 Oncology chemistry MCF-7 Drug Resistance Neoplasm Apoptosis Cancer research biology.protein Growth inhibition |
Zdroj: | Cancer Letters. 161:27-34 |
ISSN: | 0304-3835 |
DOI: | 10.1016/s0304-3835(00)00579-6 |
Popis: | Comparison of LCC2, the E(2)-independent, tamoxifen-resistant subline of the MCF-7 human breast cancer cell line with its parent line, disclosed that it is more resistant to growth inhibition and apoptosis induction by a variety of agents acting by diverse mechanisms. Thus, LCC2 cells can serve as a useful in-vitro model for the study of the molecular mechanisms of this resistance. It was found that bcl-2 protein and mRNA were elevated and that bax protein and mRNA were reduced in LCC2 compared with MCF-7 cells. Incubation of both lines in the presence of bcl-2 antisense caused growth inhibition and reduced bcl-2 protein levels only in MCF-7 cells, suggesting the involvement of bcl-2 in the regulation of normal growth of breast cancer cells. Increased bcl-2 expression in breast cancer cells may correlate with their resistance to growth inhibitory agents. Bcl-2 is a useful target for enhancing the effects of growth inhibitory agents. |
Databáze: | OpenAIRE |
Externí odkaz: |